944073-03-4

Basic information

• Product Name: (3S)-2-[Boc-L-lysinyl(Z)]-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester
• Synonyms: (3S)-2-[Boc-L-lysinyl(Z)]-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester
• CAS NO: 944073-03-4
• Molecular Weight: 592.692
• Mol File: 944073-03-4.mol

Chemical Properties

• CAS DataBase Reference: (3S)-2-[Boc-L-lysinyl(Z)]-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-2-[Boc-L-lysinyl(Z)]-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester(944073-03-4)
• EPA Substance Registry System: (3S)-2-[Boc-L-lysinyl(Z)]-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester(944073-03-4)

Safety Data

• Hazardous Substances Data: 944073-03-4(Hazardous Substances Data)

Upstream product

• 2389-45-9 Boc-Lys(Z)-OH 
• 79815-18-2 methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylate 
• 42438-90-4 3-carboxy-1,2,3,4-tetrahydro-2-carboline 
• 73-22-3 L-Tryptophan 

Downstream Products

• 945651-07-0 (3S,12aS)-3-(4'-benzyloxycarbonylaminobutyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 
• 1220974-14-0 3S-2-(Boc-lysinyl(Z))-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid 

Relevant articles and documents

A class of 3 S -2-aminoacyltetrahydro-β-carboline-3-carboxylic acids: Their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency

3S-Tetrahydro-β-carboline-3-carboxylic acid (TCCA) effectively inhibits ADP-induced platelet activation. This paper used TCCA as a lead, modified its 2-position with amino acids, and provided 20 novel 3S-2-aminoacyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acids (5a-t). With the in vitro assay, it was demonstrated that this modification diminished the IC50 values from 701 nM of TCCA to 10 nM of 5a-t. With the in vivo assay, it was demonstrated that this modification reduced the efficacious dose from 5.0 μmol/kg of TCCA to 0.1 μmol/kg of 5a-t. Comparing the Cerius2 based conformation of them with that of their analogues, the 3-position modified TCCA, it was suggested that the comparatively unfolded conformation was one of the important factors of enhancing the in vivo antithrombotic potency.

Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues

In this study, we report the design and synthesis of a series of new simplified fumitremorgin C analogues. The preliminary biological study indicated some of these simplified fumitremorgin C might be developed into breast cancer resistance inhibitors.